All-Cause Mortality in Patients With Diabetes Under Treatment With Dapagliflozin: A Population-Based, Open-Cohort Study in The Health Improvement Network Database | Zendy

Konstantinos A. Toulis | Zendy; Brian H Willis | Zendy; Tom Marshall | Zendy; Balachandran Kumarendran | Zendy; Krishna Gokhale | Zendy; Sandip Ghosh | Zendy; G. Neil Thomas | Zendy; Kar Keung Cheng | Zendy; Parth Narendran | Zendy; Wasim Hanif | Zendy; Krishnarajah Nirantharakumar | Zendy

Open Access

All-Cause Mortality in Patients With Diabetes Under Treatment With Dapagliflozin: A Population-Based, Open-Cohort Study in The Health Improvement Network Database

Author(s) -

Konstantinos A. Toulis,

Brian H Willis,

Tom Marshall,

Balachandran Kumarendran,

Krishna Gokhale,

Sandip Ghosh,

G. Neil Thomas,

Kar Keung Cheng,

Parth Narendran,

Wasim Hanif,

Krishnarajah Nirantharakumar

Publication year - 2017

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2016-3446

Subject(s) - dapagliflozin , medicine , empagliflozin , context (archaeology) , population , cohort study , confidence interval , type 2 diabetes mellitus , cohort , hazard ratio , rate ratio , relative risk , diabetes mellitus , environmental health , endocrinology , paleontology , biology

Empagliflozin was found to decrease mortality in patients with type 2 diabetes mellitus (T2DM) and a prior cardiovascular disease (CVD) event.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research